Benefits
Senolytic Activity (Eliminates Senescent Cells)
Yousefzadeh 2018 (Mayo Clinic) screening identified fisetin as the most potent natural senolytic among tested flavonoids. Selectively eliminates senescent ('zombie') cells that accumulate with age and drive chronic inflammation/aging. Animal evidence shows extended healthspan with intermittent fisetin dosing.
Anti-Inflammatory Effects
Reduces inflammatory cytokine production via NF-κB inhibition, reduces SASP (senescence-associated secretory phenotype) markers. Particularly relevant for chronic age-related inflammation ('inflammaging').
Neuroprotection (Animal Evidence)
Animal models of Alzheimer's, Parkinson's, and traumatic brain injury show neuroprotective effects. Human translation pending.
Cardiovascular Support
Antioxidant and anti-inflammatory effects in vascular tissue. Modest clinical evidence; mostly mechanistic and animal data.
Antioxidant Activity
Direct free radical scavenging and Nrf2 pathway activation — supports endogenous antioxidant defense systems.
Mechanism of action
Senolytic Pathway — BCL-2 Family Modulation
Senescent cells survive via upregulated anti-apoptotic proteins (BCL-2, BCL-xL). Fisetin inhibits these survival pathways, triggering apoptosis selectively in senescent cells. Healthy cells have lower BCL-2 dependency and are spared. Mechanism is dose-dependent and requires high concentrations — basis for HIT (high-intensity intermittent) dosing protocols.
PI3K/Akt/mTOR Inhibition
Fisetin inhibits PI3K/Akt/mTOR signaling — pathway involved in cellular senescence maintenance. Reduces SASP factors that drive inflammaging.
NF-κB and Inflammatory Pathway Inhibition
Reduces inflammatory cytokine production at multiple levels — TNF-alpha, IL-6, IL-8 reduction in vitro and in vivo.
Nrf2 Activation
Activates Nrf2-Keap1 pathway, upregulating endogenous antioxidant enzymes (glutathione synthase, SOD, catalase, NQO1). Adaptive antioxidant response.
Clinical trials
Screening study of 10 flavonoid compounds for senolytic activity in vitro and in aged mice. Mayo Clinic.
Cell culture and aged mice.
Fisetin identified as most potent natural senolytic — reduced senescent cell burden in multiple tissues, extended healthspan markers in aged mice. Generated significant clinical interest. Established mechanism for HIT senolytic protocols.
Mayo Clinic Phase 2 trial of fisetin (20 mg/kg × 2 days monthly) for frailty in older adults. NCT03675724 + related protocols.
Older adults with frailty.
Trials ongoing; results pending. Notably, this is one of few HUMAN trials testing senolytic protocols with established outcome measures. Will provide important data on whether mouse senolytic effects translate to clinical benefit in humans.
About this ingredient
Fisetin (3,3',4',7-tetrahydroxyflavone) is a FLAVONOID found primarily in STRAWBERRIES (highest concentration ~160 µg/g), apples, persimmons (~10.5 mg/g), onions, grapes, cucumbers. Distinguished as one of the MOST POTENT NATURAL SENOLYTICS identified in Mayo Clinic screening (Yousefzadeh 2018). DOSING PARADIGMS: (1) CONTINUOUS DAILY — 100-500 mg/day for general antioxidant/anti-inflammatory effects; (2) HIT (HIGH-INTENSITY INTERMITTENT) SENOLYTIC PROTOCOL — 20 mg/kg body weight × 2 consecutive days, repeated monthly; for typical 70 kg adult ≈ 1,400 mg × 2 days monthly; based on pharmacology of senolytic effects requiring high transient concentrations to overcome senescent cell survival pathways.
SOURCES & BIOAVAILABILITY: ORAL BIOAVAILABILITY VERY LOW (~5%); standard fisetin powder achieves plasma levels far below those used in cell culture senolytic studies; LIPOSOMAL FISETIN, NOVUSETIN®, and other enhanced-absorption formulations improve bioavailability significantly.
EVIDENCE-BASED USES: (1) Senolytic intermittent protocols (animal evidence strong; human clinical data PENDING from Mayo Clinic AFFIRM-LITE and related trials); (2) Anti-inflammatory; (3) Antioxidant; (4) General longevity stack component.
CRITICAL CAUTIONS: (1) HUMAN CLINICAL DATA IS LIMITED — most evidence is preclinical (cell culture, mouse models); senolytic mouse extrapolation to human aging is encouraging but not yet definitively validated; do not expect dramatic 'anti-aging' effects from current evidence base; (2) HIT PROTOCOL DOSING — high intermittent doses theoretical safety has limited human data; well-tolerated in early trials but long-term effects unknown; (3) BIOAVAILABILITY — standard fisetin may not achieve plasma concentrations needed for senolytic effects; LIPOSOMAL or other enhanced formulations preferred for senolytic protocols; (4) ANTICOAGULANTS — theoretical bleeding risk especially at HIT doses; pre-surgery discontinuation; (5) DIABETES MEDICATIONS — modest hypoglycemic effect; monitor; (6) CHEMOTHERAPY — fisetin's effects on apoptosis/proliferation theoretical interaction with chemo agents; consult oncologist; (7) IMMUNOSUPPRESSANTS — anti-inflammatory effects could theoretically interfere with intentional immunomodulation; (8) PREGNANCY/LACTATION — insufficient safety data; AVOID; (9) CHILDREN — not appropriate; senescent cells are normal aging phenomenon, not childhood concern; (10) DRUG INTERACTIONS — fisetin inhibits some CYP enzymes in vitro; theoretical effects on drug metabolism; (11) BRYAN JOHNSON BLUEPRINT and similar longevity protocols feature fisetin — rationale based on Mayo Clinic preclinical research; clinical translation evidence is pending; (12) SAFER POSITIONING — for general antioxidant/inflammatory benefit, daily dietary fisetin from strawberries/persimmons + low-dose continuous supplementation has reasonable risk profile; HIT senolytic protocols are more experimental.